China channel feed – Endpoints News

China channel feed

Singaporean biotech gets China thumbs-up for study of potentially curative HBV cell therapy

Yesterday

Bristol Myers' China partner touts Phase 3 success for EGFRxHER3 bispecific ADC

6 days ago

China’s rise splits US biotech investors: Cash in, or counter?

Last week

Innovent brings a new mechanism to obesity market with China approval

Last week

Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

3 weeks ago

Watch Post-Hoc Live: China is still the top conversation starter at BIO

3 weeks ago

NextCure inks ADC deal with Shanghai drugmaker

4 weeks ago

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

4 weeks ago

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

Last month

Sagimet's stock rises after China partner reports positive Phase 3 data in acne

Last month

Regeneron makes $80M obesity deal with Hansoh

Last month

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Last month

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Last month

TCG's R&D venture team makes a T cell engager deal with Shanghai biotech

Last month

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Last month

Updated: Merck KGaA continues US tariff surcharge but at a 'decreased' rate

Last month

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

Last month

Early bits of in vivo CAR-T human data emerge from biotech trials in China

2 months ago

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

2 months ago

AstraZeneca, Novartis execute ‘US for US’ strategy as pharma tariffs near

2 months ago

AstraZeneca posts another Truqap study fail, says China import tax could triple

2 months ago

WuXi AppTec sees growth after 2024 dip, plans ‘lean’ operations to temper ‘external opportunities’

2 months ago

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

2 months ago

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

2 months ago

12 3 4 Next page Last page